NASDAQ:NSTG - NanoString Technologies Stock Price, News & Analysis

NanoString Technologies trades on the NASDAQ under the ticker symbol "NSTG."

NanoString Technologies Inc (NASDAQ:NSTG) announced its quarterly earnings results on Wednesday, July, 31st. The biotechnology company reported ($0.57) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.55) by $0.02. The biotechnology company earned $30.35 million during the quarter, compared to the consensus estimate of $29 million. NanoString Technologies had a negative net margin of 68.16% and a negative return on equity of 118.03%. View NanoString Technologies' Earnings History.

NanoString Technologies is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for NanoString Technologies.

NanoString Technologies updated its FY 2019 earnings guidance on Wednesday, July, 31st. The company provided EPS guidance of $-2.4--2.2 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $-2.24. The company issued revenue guidance of $118-123 million, compared to the consensus revenue estimate of $120.83 million.

3 brokers have issued 12 month target prices for NanoString Technologies' stock. Their predictions range from $18.00 to $35.00. On average, they anticipate NanoString Technologies' stock price to reach $25.3333 in the next twelve months. This suggests a possible upside of 15.9% from the stock's current price. View Analyst Price Targets for NanoString Technologies.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NanoString Technologies in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NanoString Technologies.

News coverage about NSTG stock has trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NanoString Technologies earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for NanoString Technologies.

Some companies that are related to NanoString Technologies include Crispr Therapeutics (CRSP), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Audentes Therapeutics (BOLD), Coherus Biosciences (CHRS), Orchard Therapeutics (ORTX), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Alector (ALEC), Sangamo Therapeutics (SGMO), Editas Medicine (EDIT), Fate Therapeutics (FATE) and Aerie Pharmaceuticals (AERI).

Based on aggregate information from My MarketBeat watchlists, some companies that other NanoString Technologies investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Aegean Marine Petroleum Network (ANW), Chipotle Mexican Grill (CMG), Precision Drilling (PD), AutoZone (AZO), Bank Of The Ozarks (OZRK), Designer Brands (DSW) and Eaton Vance Floating-Rate Income Trust (EFT).

NanoString Technologies' stock is owned by a number of of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (10.06%), Morgan Stanley (9.15%), BlackRock Inc. (8.73%), Nikko Asset Management Americas Inc. (7.10%), Vanguard Group Inc. (4.88%) and Cadian Capital Management LP (4.31%). Company insiders that own NanoString Technologies stock include Charles P Waite, Jr, David W Ghesquiere, K Thomas Bailey, Kirk Malloy, Lifesciences Ii LP Clarus, Mary Tedd Allen, Nicholas Galakatos, R Bradley Gray and William Young. View Institutional Ownership Trends for NanoString Technologies.

NSTG stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Bank of America Corp DE, Farallon Capital Management LLC, Cubist Systematic Strategies LLC, Platinum Investment Management Ltd., Bogle Investment Management L P DE, Sandler Capital Management and Lisanti Capital Growth LLC. Company insiders that have sold NanoString Technologies company stock in the last year include Charles P Waite, Jr, David W Ghesquiere, K Thomas Bailey, Kirk Malloy, Lifesciences Ii LP Clarus, Mary Tedd Allen, Nicholas Galakatos, R Bradley Gray and William Young. View Insider Buying and Selling for NanoString Technologies.

NSTG stock was purchased by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Cadian Capital Management LP, BlackRock Inc., Nuveen Asset Management LLC, Sumitomo Mitsui Trust Holdings Inc., Wells Fargo & Company MN, Vanguard Group Inc. and Citadel Advisors LLC. View Insider Buying and Selling for NanoString Technologies.

Shares of NSTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NSTG stock can currently be purchased for approximately $21.85.

NanoString Technologies has a market capitalization of $774.36 million and generates $106.73 million in revenue each year. The biotechnology company earns $-77,400,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. NanoString Technologies employs 476 workers across the globe.View Additional Information About NanoString Technologies.

The official website for NanoString Technologies is http://www.nanostring.com/.

NanoString Technologies' mailing address is 530 FAIRVIEW AVENUE NORTH SUITE 2000, SEATTLE WA, 98109. The biotechnology company can be reached via phone at 206-378-6266 or via email at [email protected]